Introduction {#S1}
============

Bacterial killing assays in whole blood are well established and allow *ex vivo* assessment of immune function in patients, particularly in the context of assessing response to vaccines or evaluating new bactericidal therapies ([@B1]--[@B4]). The main read out of these assays is microbial killing measured *via* culture and colony counting, or fluorescence if reporter strain organisms are used.

Potential problems of these microbiological killing assays include difficulties in standardizing the number of microbes and their multiplication rate. The tendency of the microbes to aggregate inconsistently during assays may also result in misrepresentation of the actual numbers of microbes measured at the end of the assay. In addition, there are other factors that can result in microbial loss that are not dependent on the host immune response or antimicrobial therapy ([@B5]). Finally, because the read out is simply bacterial survival, these assays lack the ability to differentiate mechanisms of killing and the relative contributions of the different phagocyte lineages present in the blood.

Phagocytosis is an important mechanism in the microbial killing pathway of phagocytes. Deficiencies in phagocyte function likely predispose individuals to acquire or succumb to infectious diseases. An extensive range of dynamic assays of phagosome function have been developed that are capable of providing a broad range of physiological readouts from the phagosome ([@B6], [@B7]). These assays have mostly utilized inert beads derivatized with different fluorescent reporters and focused on human alveolar macrophages or murine bone marrow-derived macrophages in culture ([@B8]--[@B10]). By removing cells from whole blood or their usual tissue fluid, we are unable to assess the potentially important influence of soluble proteins such as cytokines, chemokines, or antibodies on phagocytosis and phagosomal behavior. We therefore sought to develop an assay using a reporter particle more suitable for probing phagocyte biology in whole blood. The assay is designed to provide reproducible, unbiased, real-time analysis of phagosomal function of immune cells and potentially identify patients with impaired immune responses.

We utilized zymosan derivatized with the oxidation-sensitive fluorescent reporter, OxyBURST-SE, to quantify phagosomal oxidase activity in peripheral blood phagocytes *in situ*. Zymosan is a preparation of a cell wall glucan from *Saccharomyces cerevisiae* that has been used as a model microbial particle in immune assays for over half a century ([@B11]). Zymosan is highly mannosylated and linked to β-glucan, making it susceptible to phagocytosis by monocytes, polymorphonuclear leukocytes, and macrophages through various receptors, including C-type lectin receptors such as dectin-1 and mannose receptors ([@B12], [@B13]). Phagocytosis of zymosan can occur independent of opsonization, of which complement factor 3 (C3) predominates with immunoglobulin G (IgG) being of minor importance ([@B14]). Zymosan also stimulates an inflammatory cytokine response *via* toll-like receptors (TLR) 2 and 6, although activation of these receptors is not required for internalization by phagocytes ([@B12]). We had demonstrated previously how inert particles coupled to OxyBURST-SE can be used to quantify the superoxide bust of murine macrophages *in vitro* ([@B15]).

Superoxide burst is one of the key enzymatic activities involved in killing microbes during the process of phagocytosis. The generation of oxygen radicals *via* nicotinamide adenine dinucleotide phosphate (NADPH) oxidase leads to the production of noxious compounds such as hydrogen peroxide with potent antimicrobial activity ([@B16], [@B17]). Superoxide burst's importance is clearly demonstrated by the greatly increased risk of bacterial, fungal, and mycobacterial infection in patient with chronic granulomatous disease due to mutations in NADPH oxidase ([@B18]). It has also been shown to be suppressed in individuals with HIV infection ([@B19]) and by *Mycobacterium tuberculosis* (TB) infection *in vitro* ([@B20]).

In this study, we report the application of this novel reporter platform to quantify the phagocytic and superoxide burst functions of phagocytes in whole blood obtained from individuals in a clinical setting. First, we detail the information generated by application of the assay in whole blood from healthy controls. We then present data showing the utility of this assay in demonstrating the perturbation of phagocyte function in the blood from HIV- and TB-coinfected patients in Malawi.

Materials and Methods {#S2}
=====================

Study Population {#S2-1}
----------------

Adult patients with HIV and tuberculosis coinfection (HIV-TB) were recruited as part of a sub-study examining immune responses in the Malawi arm of the rapid urine-based screening for TB to reduce AIDS-related mortality in hospitalized patients in Africa (STAMP) ([@B21]). Healthy HIV-negative adults with no evidence of active TB were also recruited as controls. 5 ml of blood was collected from both patients and controls in sodium heparin tubes. All samples were processed and analyzed by flow cytometry at the Malawi-Liverpool-Wellcome Trust Clinical Research Programme in Blantyre, Malawi within 2 h of blood draw. The study has been approved by the London School of Hygiene & Tropical Medicine Research Ethics Committee and the College of Medicine Research Ethics Committee, Malawi.

Zymosan Reporter Particles {#S2-2}
--------------------------

To quantify both phagocytic activity and the magnitude of the superoxide burst we utilized zymosan particles coupled to both a calibration fluorochrome (Alexa Fluor 405-SE, Invitrogen) and an oxidation-sensitive fluorescent reporter (OxyBURST^®^ Green H~2~DCFDA-SE, Invitrogen). Zymosan reporter particles were prepared by washing 6 mg of zymosan (Sigma-Aldrich) three times in 1× phosphate-buffered saline (PBS) by centrifugation at 10,000 rpm for 1 min. Particles were resuspended in 950 µl coupling buffer (0.1 M boric acid to pH 8.0 with NaOH) containing 10 µl of 25 mg/ml OxyBURST-SE/DMSO stock solution and 5 µl of 5 mg/ml Alexa Fluor 405-SE/DMSO solution. The particles were mixed well and incubated on a tube rocker in the dark for 1 h at room temperature and washed with 1 ml of coupling buffer. The 1 h coupling with OxyBURST-SE and calibration fluorochrome was repeated twice. Finally, particles were washed three times with PBS and stored in 1 ml of PBS containing 0.01% sodium azide in the dark at 4°C generating a final stock concentration of approximately 5 × 10^6^ particles/ml.

Whole Blood Assay {#S2-3}
-----------------

Zymosan reporter particles were prepared for the whole blood assay by washing 50 µl of stock Zymosan particle suspensions three times with 1 ml of RPMI-1640 to remove sodium azide and resuspended in 250 µl RPMI-1640 to give a 1:6 dilution and a final concentration of approximately 8 × 10^5^ particles/ml.

Whole blood was diluted 1:1 with warm RPMI-1640. 20 µl of washed and diluted reporter particles (containing approximately 2 × 10^4^ particles) were added to 1 ml of diluted blood and incubated at 37°C with rocking to ensure particles and cells remain in suspension. Diluted blood without zymosan reporter particles was also processed in parallel as control. Phagocytosis of zymosan reporter particles and superoxide burst was assessed at 10, 30, 60, 90, and 180 min after the addition of reporter particles.

100 µl of diluted blood was harvested from the zymosan reporter and biological control tubes 10 min before each time point for cell surface staining (as phagocytosis continues during cell surface staining of live cells). Once harvested, the diluted blood was stained with appropriately titrated concentrations of antibodies (anti-CD45 PerCP 1:33, anti-CD66b APC 1:50, and anti-CD14 PE-Cy7 1:100; all from BioLegend) for 10 min. Biological activity was arrested, red blood cells were lysed, and leukocytes fixed by adding 3 ml of BD FACS lysing solution (BD Biosciences), containing formaldehyde and diethylene glycol, to each tube and incubating at room temperature for 10 min. The cells were washed once with 1× PBS by centrifugation at 500 *g* for 10 min then resuspended in 500 µl 1× PBS. Counting beads (Countbright, Life Technologies) were added per the manufacturer's instruction before acquisition on a CyAn ADP flow cytometer (Beckman Coulter, USA). The phagocytosis assay was performed in triplicate on the whole blood samples from healthy, HIV-negative adults. Data were analyzed using FlowJo version 10 (Treestar, USA).

In addition to the zymosan reporter assay, for HIV/TB-coinfected patients, immunophenotyping of monocytes in fresh whole blood was undertaken to investigate the association between monocyte phenotype and phagocytosis. In brief, 100 µl of fresh whole blood was stained with anti-CD45 Pacific Orange (Invitrogen), anti-HLA-DR PE-Cy7, anti-CD14 PE, and anti-CD16 FITC (all from BioLegend) for 10 min. Red blood cells were lysed, and leukocytes fixed with BD FACS lysing solution, washed once with 1× PBS by centrifugation at 500 *g* for 10 min then resuspended in 300 µl PBS for flow cytometry acquisition.

Electron Microscopy (EM) {#S2-4}
------------------------

In parallel, 2 ml of whole blood from a healthy HIV-negative control was incubated with approximately 8 × 10^4^ zymosan reporter particles to confirm the zymosan particles were internalized by whole blood phagocytes. White blood cells were harvested after 10, 60, and 180 min by centrifugation at 500 *g* for 10 min and carefully pipetting out the buffy coat layer in buffered glutaraldehyde fixative solution (2.5% glutaraldehyde in 0.1 M sodium cacodylate, 5 mM CaCl~2~, 5 mM MgCl~2~, 0.1 M sucrose, pH 7.2). The samples were processed and stained for EM as described previously ([@B22]).

Calculations and Statistical Analysis {#S2-5}
-------------------------------------

The proportion of cells that had phagocytosed reporter particles was calculated based on expression of calibration fluorochrome, and absolute cell numbers calculated using counting beads. An "activity index" of phagocytosis and superoxide burst was calculated by subtracting the median fluorescence intensity of the negative cells from the positive cells, and dividing this by two times the robust SD of the negative cells ([@B23]). This method accounted for variations in auto fluorescence between cells from different individuals.

Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, USA) and Stata 11 (StataCorp, USA). Peak activity index (AI) was calculated and mean AI was compared between groups. The AI at each time point was also used to calculate the area under the curve. Means were compared using paired *t*-tests and median using Wilcoxon rank-sum.

Results/Discussion {#S3}
==================

Zymosan Uptake by Whole Blood Phagocytes {#S3-1}
----------------------------------------

We used whole blood from four healthy HIV-negative controls to measure phagocytosis and superoxide burst of phagocytes *ex vivo* using zymosan-reporter particles. We first sought to determine the kinetics of zymosan uptake by whole blood phagocytes. The flow cytometry gating strategy to identify neutrophils and monocytes is outlined in Figure [1](#F1){ref-type="fig"}. Cells that had phagocytosed zymosan-reporter particles were identified and quantified through measurement of the calibration fluor, Alexa Fluor 405.

![Gating strategy for identification of phagocytes with zymosan reporter particles and quantitation of intraphagosomal oxidation. **(A)** Gating strategy displaying forward scatter (FSC), side scatter (SSC), CD45 PerCP, CD66b APC, and CD14 PE-Cy7 to identify neutrophils and monocytes. The gating strategy illustrated is from one representative healthy volunteer. **(B)** Zymosan-induced superoxide burst activity in neutrophils and monocytes in a healthy control. The OxyBURST fluorescence increases after intraphagosomal oxidation of the zymosan-reporter particles (Alexa Fluor 405-labeled) after 10 and 60 min compared with control sample with no zymosan-reporter particles. **(C)** Overlay histogram demonstrating the shift in fluorescence of cells with zymosan reporter particles due to oxidation after 10 min (red), 30 min (orange), and 60 min (blue) compared with cells without zymosan-reporter particles (green) for both neutrophils and monocytes.](fimmu-08-01222-g001){#F1}

Zymosan particles were avidly internalized by both neutrophils and monocytes in blood from healthy controls. Uptake was rapid, with a mean of 26% of neutrophils phagocytosing the particles compared with 12% of monocytes by 30 min (Figure [2](#F2){ref-type="fig"}A). The proportion of neutrophils phagocytosing zymosan did not increase substantially between 30 and 180 min, whereas the percentage of monocytes associated with zymosan-reporter particles increased gradually during the assay. This pattern of uptake was consistent across all healthy controls.

![Phagocytosis of zymosan reporter particles by monocytes and neutrophils. **(A)** Proportion of cells that have phagocytosed zymosan over time using blood from healthy individuals incubated with approximately 2 × 10^4^ zymosan particles/ml. Data represent mean values, and the error bars indicate SEM. Concentration of neutrophils **(B)** and monocytes **(C)** that have internalized zymosan reporter particles over time, with varying concentrations of particles. Relationship between the proportion of cells internalizing zymosan reporter particles (at an approximate concentration of 2 × 10^4^ zymosan particles/ml) and absolute cell concentration for neutrophils **(D)** and monocytes **(E)** after 60 min. Each data point represents one sample from each individual done in triplicate. Four healthy volunteers in triplicate are shown in panels **(A,D,E)**, and one health volunteer is shown in panels **(B,C)**.](fimmu-08-01222-g002){#F2}

The uptake of zymosan reporter particles by both monocytes and neutrophils is dose dependent as shown in the dose--response curve generated for 0.5 × 10^4^--8 × 10^4^ zymosan particles/ml (Figure [2](#F2){ref-type="fig"}B). The abundance of the phagocytic cells in whole blood also influences the overall proportion of cells phagocytosing zymosan particles (Figure [2](#F2){ref-type="fig"}C). The higher the concentration of cells, the lower the proportion of cells carrying the zymosan-reporter signal, shown for both neutrophils and monocytes (Figures [2](#F2){ref-type="fig"}D,E). This relationship persists throughout the assay and demonstrates the importance of the phagocyte to particle ratio in the kinetics of phagocytosis. Relying solely on internalization of particles to assess phagocytic function is a potential limitation of the assay, as the magnitude of phagocytosis may be influenced by a function of cell concentration and/or cell to particle ratio, rather than cellular deficiencies in phagocytic capacity.

Electron microscopy of white blood cells from a healthy control whole blood incubated with zymosan particles demonstrates phagocytosis of zymosan particles by peripheral blood phagocytes (Figure [3](#F3){ref-type="fig"}). The EM images support the assumption that the zymosan reporter signal detected by flow cytometry originates from phagocytosis rather than the association of zymosan particles with the phagocyte surface. Almost without exception, the zymosan particles were observed inside the phagocyte.

![Assessment of phagocytosis of zymosan reporter particles by electron microscopy. An electron micrograph illustrating zymosan particles (Z) inside a neutrophil 60 min post incubation of the reporter particles with whole blood. A red blood cell (R) can be seen to the right of the neutrophil. This image is representative and indicates that the zymosan particles are effectively internalized by cells in suspension. The scale bar = 1 µm.](fimmu-08-01222-g003){#F3}

Cell Loss Associated With Zymosan {#S3-2}
---------------------------------

To examine the effect of the zymosan particles on cell loss, we compared the samples containing zymosan reporter particles and control samples from the same healthy individuals. The mean concentration of neutrophils and monocytes declined during the assay more rapidly in the presence of zymosan than in control samples, with the largest decline occurring between 90 and 180 min (Figures [4](#F4){ref-type="fig"}A,B).

![Cell concentrations and activity index (AI) of superoxide burst over time. The concentration of neutrophils **(A)** and monocytes **(B)** at different time points from HIV-negative control samples without zymosan (green), and samples incubated with zymosan reporter beads that had internalized zymosan (blue) or did not internalize zymosan (red). In **(C)** neutrophils and **(D)** monocytes, each color represents the superoxide AI data from different individuals. The AIs are from four healthy, HIV-negative individuals, each performed in triplicate.](fimmu-08-01222-g004){#F4}

Furthermore, the concentration of neutrophils associated with zymosan-reporter signal peaked at 60 min, followed by a decline (Figure [4](#F4){ref-type="fig"}A). By contrast, the concentration of zymosan-associated monocytes plateaus at 30 min (Figure [4](#F4){ref-type="fig"}B). However, in both cell types the peak in zymosan uptake coincided with cell loss, suggesting that zymosan plays a role in inducing cell death. This is also supported by increased cell loss at higher concentrations of zymosan in the assay (Figure [2](#F2){ref-type="fig"}B).

These observations are consistent with neutrophil and monocyte biology. Neutrophils are known to have a short half-life *in vitro*, estimated to be 6--12 h, and do not proliferate ([@B24]). Programmed cell death of neutrophils occurs rapidly following phagocytosis of inflammatory particles, and reactive oxygen species may be important triggers for induction of apoptosis ([@B20]). In neutrophils that have not phagocytosed zymosan particles, activation *via* direct binding of zymosan to TLR2 and TLR6 or in response to inflammatory cytokine and chemokine production may also contribute to cell death ([@B12]). By contrast, monocytes have an estimated half-life of \<20 h *in vivo*, although this may be shorter *ex vivo* ([@B25]). Monocytes also undergo programmed cell death, unless they migrate to tissues and undergo differentiation into tissue macrophages ([@B26]). However, in contrast to neutrophils, inflammatory cytokine production and stimulation *via* TLR2 can promote survival by blocking programmed cell death ([@B27]). This may explain why monocytes that had phagocytosed zymosan reporter particles did not substantially decrease in number during the assay.

Phagocytosis and Superoxide Burst {#S3-3}
---------------------------------

Superoxide burst activity was measured at 10, 30, 60, 90, and 180 min by comparing fluorescence of cells that had internalized zymosan reporter particles (calibration fluor-positive cells) with the cell population without zymosan (calibration fluor-negative cells) through measurement of the OxyBURST, superoxide sensor signal. The proportion of cells and intensity of superoxide reporter fluorescence increased over the time course of the assay in both monocytes and neutrophils (Figures [1](#F1){ref-type="fig"}B,C). The intensity of the calibration fluorochrome signal did not increase over time, suggesting the increase in superoxide reporter signal was not due to cells internalizing greater numbers of zymosan-reporter particles but was specific to the oxidase activity (Figure [1](#F1){ref-type="fig"}B).

Both peripheral blood monocytes and neutrophils showed rapid oxidation within 30--60 min (Figures [4](#F4){ref-type="fig"}C,D). The kinetics of oxidation in neutrophils and monocytes were similar to macrophages in other studies, with rapid oxidation before an equilibrium being reached, which likely represents cessation of NADPH oxidase activity ([@B6], [@B15]).

When the concentration of zymosan reporter particles was varied, the AI remained constant despite the concentration and proportion of cells taking up zymosan changing. This indicates the assay is able to measure physiological changes in the intensity and duration of phagocytosis and superoxide burst within the phagosome at an individual cell level. This is a significant advance over existing assays, which measure the extracellular accumulation of products of oxidation that is dependent on the summation of phagocytosis and superoxide burst ([@B28]). Moreover, because this assay has cellular resolution, the relative contribution of the different phagocyte subsets can be accurately measured. We have also demonstrated that the assay is reproducible with minimal intraindividual variation.

Assays using OxyBURST coupled to IgG coated beads have previously been used to investigate oxidation within macrophage phagosomes ([@B6], [@B15]), and more recently in whole blood ([@B29]). The current assay exploiting zymosan as a reporter particle is an important addition to the range of phagocyte functional assays and offers considerable practical and technical advantages in the functional interrogation of whole blood direct from human subjects of interest.

Assessment of Whole Blood Phagocyte Function in Patients with HIV/TB Coinfection {#S3-4}
--------------------------------------------------------------------------------

The zymosan reporter assay was performed on blood samples obtained from 18 hospitalized HIV-positive patients with laboratory confirmed TB disease to compare phagocytic and superoxide respiratory burst activity in the phagosome between patients and healthy, HIV-negative, controls. The HIV/TB patients had a mean age of 41.4 years, a median CD4 cell count of 108.5 cells/mm^3^ and 13/18 were taking antiretroviral therapy at the point of hospital admission. The HIV/TB-coinfected patients demonstrated marked variation in phagosomal oxidation activity compared with healthy controls. The kinetics were similar to healthy controls with peak activity occurring at 30 min, although overall mean intensity of superoxide burst was significantly reduced throughout the assay (paired *t*-test, all *p* \< 0.0001) (Figure [5](#F5){ref-type="fig"}A). There was also a strong association between increased monocyte superoxide burst activity and the presence of a higher proportion of "classical" CD14^++^CD16^−^ monocytes (Figure [5](#F5){ref-type="fig"}B, linear regression coefficient 0.0014, 95% CI 0.0005--0.0024, *p* = 0.006). This association is consistent with the suggestion that classical monocytes are thought to specialize in phagocytosis compared with other monocyte subsets ([@B30]). However, the superoxide activity in monocytes was not related to the overall concentration of monocytes in patient's blood (linear regression slope 0.0002, 95% CI −0.0002 to 0.0005, *p* = 0.19), supporting the contention that the superoxide AI was not simply a function of phagocyte abundance.

![Phagocytosis, superoxide burst, and monocyte phenotypes in peripheral blood phagocytes of HIV/tuberculosis (TB)-coinfected patients. **(A)** The superoxide burst activity index (AI) over time comparing cells from healthy individuals (blue) with cells from HIV/TB-coinfected patients (red). Lines represent means, and error bars are 95% CI. Mean AIs were lower in the HIV/TB patients at all time points analyzed (paired *t*-tests, all *p* \< 0.0001). **(B)** The association between the proportion of HLA-DR^+^ monocytes that are CD14^++^CD16^−^ (classical), CD14^+^CD16^+^ (intermediate), and CD14^−^CD16^+^ (non-classical), and monocyte phagocytosis and superoxide burst AI (measured as "area under the curve"). There is a strong association between higher proportions of classical monocytes and increased AI (*p* = 0.006) (*n* = 18). The data in panel **(A)** are from four health volunteers in triplicate, and the data in panel **(B)** are from 18 HIV/TB patients.](fimmu-08-01222-g005){#F5}

These data demonstrate that the whole blood assay with zymosan reporter particles is a robust tool for assessing phagocyte function in a clinical setting. The time required to run the assay once the reporter particles have been made is minimal, with the processing of the sample through to acquisition by flow cytometry taking less than 4 h. We also demonstrated this assay can show marked differences between individuals and groups of patients based on clinical phenotype. It is interesting to note that the reduced superoxide burst in the phagocytes from HIV/TB-coinfected individuals observed in this study is consistent with a recent report of impaired innate immune function of monocytes from HIV/TB-coinfected patient cohort in South Africa ([@B31]).

Concluding Remarks {#S4}
==================

We present a new method for studying whole blood phagocyte functional capacity *ex vivo*. This technique uses fluorescent-tagged zymosan-reporter particles and whole blood, preserving, at least in part, the physiological *in vivo* conditions. It offers several advantages over standard microbiological killing assays because of its speed and simplicity, and its increased resolution whereby cellular responses such as phagocytic capacity and superoxide burst, can be quantified at the level of the individual cell.

We have demonstrated that the assay can be used to characterize immune function and to detect perturbation of cellular function in patients with severe immunological impairment (in HIV/TB-coinfected individuals). This assay is easily adaptable to standard immunological assays based on cell surface marker expression measured by flow cytometry and has the capacity to provide direct functional readouts of immune cell activities. Previously, we have used inert reporter particles to measure rates of phagosomal acidification, intraphagosomal proteolytic and lipolytic activities, as well as superoxide burst in tissue macrophages in culture. These activities are differentially modulated by immune status and infection ([@B7]--[@B9]). The use of zymosan as an alternative, biologically active carrier particle for whole blood-based assays brings these complex biological readouts into a clinical setting for functional interrogation of patient-derived samples linked to disease status.
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